WS01.5 A 2-part, phase 3 single-arm study to evaluate the safety and pharmacokinetics (PK) of lumacaftor/ivacaftor (LUM/IVA) combination therapy in patients (pts) aged 2 to 5 years with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation

      This paper is only available as a PDF. To read, Please Download here.